Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy

Ishijima, Mikako; Nakayama, Hidetsugu; Itonaga, Tomohiro; Tajima, Yuki; Shiraishi, S.; Okubo, Masaaki; Mikami, Ryuji; Tokuuye, Koichi

doi:10.1259/bjr.20140596

Cited by 24 publications

(20 citation statements)

References 20 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,15,22,23 Recently, the risk factors of RP after SBRT in patients with lung tumours have been investigated, 19,[22][23][24][25][26][27][28][29] and some studies reported about the clinical and dosimetric risk factors of RP. 21,[29][30][31][32][33][34][35][36][37][38][39][40][41][42] Table 7 summarizes published reports of the clinical and dosimetric risk factors associated with Grade 2 or worse RP after SBRT.…”

Section: Discussionmentioning

confidence: 99%

Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours

Okubo

Itonaga

Sato

et al. 2017

BJR

View full text Add to dashboard Cite

Subclinical ILD was the only significant factor for Grade 2-5 RP. In addition, the cases with honeycombing had a high potential for fatality related to severe RP. Patients with subclinical ILD should be carefully monitored for the occurrence of severe RP after SBRT. Advances in knowledge: Hypofractionated SBRT for primary or metastatic lung tumours provides a high local control rate and safe treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours

Okubo

Itonaga

Sato

et al. 2017

BJR

View full text Add to dashboard Cite

show abstract

“…This transgenic mouse line was protected from fibrosis and mortality associated with bleomycin-induced lung injury. Furthermore, the risk of radiation pneumonitis was lower in patients with severe emphysema, such as the patients in our study, than that in patients with no underlying lung disease [18]. However, this is a hypothesis, and we intend to test this hypothesis in future studies.…”

Section: Discussionmentioning

confidence: 70%

Prognosis of patients with acute exacerbation of combined pulmonary fibrosis and emphysema: A retrospective single-center study

Ikuyama

Ushiki

Kosaka

et al. 2019

Preprint

View full text Add to dashboard Cite

BackgroundPrevious analyses of combined pulmonary fibrosis and emphysema (CPFE) cohorts have provided conflicting data on the survival of patients with CPFE. Therefore, the aim of this study was to investigate the clinical prognosis of acute exacerbation (AE) of CPFE.MethodsWe retrospectively reviewed the medical records of patients who had been treated at Shinshu University Hospital (Matsumoto, Japan) between 2003 and 2017. We identified 21 patients with AE of CPFE and 41 patients with AE of idiopathic pulmonary fibrosis (IPF) and estimated their prognoses using the Kaplan–Meier method.ResultsTreatment content and respiratory management were not significantly different between the two groups before and after exacerbation. At the time of AE, the median serum Krebs von den Lungen-6 level was significantly lower in the CPFE group (Krebs von den Lungen-6: 966 U/µL; white blood cell count: 8810 /µL) than that in the IPF group (Krebs von den Lungen-6: 2130 U/µL, p < 0.001; white blood cells: 10809/µL, p = 0.0096). The baseline Gender-Age-Physiology score was not significantly different between the two groups (CPFE, 4.5 points; IPF, 4.7 points; p = 0.58). Kaplan–Meier curves revealed that the survival time after AE for patients with CPFE was longer than that for patients with IPF (p < 0.001, log-rank test).ConclusionsSurvival prognoses after AE were significantly better for patients with CPFE than that for patients with IPF. Our findings may improve the medical treatment and respiratory management of patients with AE-CPFE.

show abstract

“…Primary radiation therapy might be proposed for patients with emphysema, impaired lung function and NSCLC but this strategy lacks the beneficial effect of lung volume reduction. Radiation therapy shows only few complications [i.e., pneumonitis (35)] but our patients after concomitant cancer resection and LVRS profit from low morbidity as well. LVRS is safe and effective in all types of emphysema morphology and therefore cancer resection heterogeneous and even in intermediately heterogeneous emphysema should be taken into account (18,20,36).…”

Section: Discussionmentioning

confidence: 94%

Improved postoperative lung function after sublobar resection of non-small-cell lung cancer combined with lung volume reduction surgery in patients with advanced emphysema

et al. 2018

View full text Add to dashboard Cite

show abstract

Patients with severe emphysema have a low risk of radiation pneumonitis following stereotactic body radiotherapy

Abstract: Little is known about the association between RP and pulmonary emphysema. Patients with severe emphysema had lower risk of RP than those with no underlying lung disease.

Cited by 24 publications

References 20 publications

Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours

Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours

Prognosis of patients with acute exacerbation of combined pulmonary fibrosis and emphysema: A retrospective single-center study

Improved postoperative lung function after sublobar resection of non-small-cell lung cancer combined with lung volume reduction surgery in patients with advanced emphysema

Contact Info

Product

Resources

About